Clinical Trials Directory

Trials / Unknown

UnknownNCT03235700

Hyperemic Efficacy of IV Adenosine in HFrEF

Hyperemic Efficacy of Intravenous Infusion of Adenosine in Heart Failure With Reduced Ejection Fraction

Status
Unknown
Phase
N/A
Study type
Interventional
Enrollment
125 (estimated)
Sponsor
Sejong General Hospital · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Little is known about the hyperemic efficacy of IV adenosine as well as safety in patients with heart failure with reduced ejection fraction (HFrEF) because they were excluded from the major FFR studies. We will evaluate the feasibility and hyperemic efficacy of IV adenosine in patients with HFrEF in comparison with IC nicorandil for invasive physiological assessment using a coronary pressure wire.

Detailed description

Little is known about the hyperemic efficacy of IV adenosine as well as safety in patients with heart failure with reduced ejection fraction (HFrEF) because they were excluded from the major FFR studies. We will evaluate the feasibility and hyperemic efficacy of IV adenosine in patients with HFrEF in comparison with IC nicorandil for invasive physiological assessment using a coronary pressure wire. Patients with an angiographically intermediate lesion (40-70% diameter stenosis) in a major epicardial coronary artery and with left ventricle ejection fraction ≤40% will be prospectively enrolled. FFR under the various hyperemic stimulation using IV adenosine 140 \& 180, IC adenosine, and IC nicorandil will be measured sequentially.

Conditions

Interventions

TypeNameDescription
OTHERMaximal hyperemia with adenosine followed by nicorandilIV adenosine 140 - IV adenosine 180 - IC adenosine (LCA 200/RCA 100) - IC nicorandil 2
OTHERMaximal hyperemia with nicorandil followed by adenosineIC nicorandil 2 - IV adenosine 140 - IV adenosine 180 - IC adenosine (LCA 200/RCA 100)

Timeline

Start date
2017-03-01
Primary completion
2020-02-28
Completion
2020-02-28
First posted
2017-08-01
Last updated
2017-08-01

Locations

1 site across 1 country: South Korea

Source: ClinicalTrials.gov record NCT03235700. Inclusion in this directory is not an endorsement.